Navigation Links
Mimicking nature at the nanoscale: Selective transport across a biomimetic nanopore
Date:6/20/2011

Researchers at Delft University of Technology and the University of Basel have established a biomimetic nanopore that provides a unique test and measurement platform for the way that proteins move into a cell's nucleus. In the journal Nature Nanotechnology (June 19 - online), they report an artificial nanopore that is functionalized with key proteins which mimicks the natural nuclear pore. Upon testing the transport of individual proteins through the biomimetic pore, they found that most proteins cannot move through, but some specific ones can indeed pass. This is the hallmark of the intriguing selectivity that is also found in natural pores. The biomimetic pore is fully functional and can be used as a testing platform for studies of drug delivery into a cell's nucleus.

The nuclear pore complex

"Human cells have a nucleus, and proteins and RNA need to get in and out. This is regulated by small holes, called nuclear pore complexes. These are essential biological pores that act as gatekeepers of the cell nucleus. They transport proteins and RNA in and out of the nucleus in a highly selective manner, which means that some go through but others are blocked from passing. There is much debate on how this intriguing selectivity is achieved. Given the fact that it is very difficult to perform high-resolution measurements in the complex environment of the living cell, the exact mechanism is hard to resolve." Professor Cees Dekker, director of the Kavli Institute of Nanoscience at Delft and leader of this research, explains. In the new research by Dekker's group in collaboration with the group of dr. Roderick Lim of the University of Basel, they were able to make a biomimetic nanopore a synthetic pore that imitates the nuclear pore which acts as a new, powerful platform to monitor transport of individual proteins across.

Biomimetic nanopore

Dekker: "One promising approach to study this nuclear transport is biomimetics the development of synthetic systems that imitate biological structures and processes. Advances in nanotechnology now make it possible to study and shape matter at the nanometer scale, opening the way to imitate biological structures at the molecular level to both study and harness their ingenuity." The group of dr. Roderick Lim at the University of Basel purified the nuclear pore proteins and Dekkers group made the biomimetic nanopores of these by attaching these proteins to small holes in a solid-state support.

Selectivity

The new research, performed chiefly by lead author Stefan Kowalczyk, a graduate student in Dekkers lab, demonstrates that it is possible to establish a biomimetic nuclear pore and to monitor transport of individual proteins across the pore. Importantly, the biomimetic pore exhibits strong selectivity, just like the natural nuclear pore complex: ImpB proteins do pass the pores, whereas BSA proteins do not (as illustrated by the attached image). A differing degree of selectivity was found, depending on which exact nuclear pore proteins were used to functionalize the pore. The researchers have shown that the biomimetic pore is fully functional and can be used as a testing platform for studies of drug delivery into a cell's nucleus.


'/>"/>

Contact: Prof. Cees Dekker
c.dekker@tudelft.nl
Delft University of Technology
Source:Eurekalert

Related biology news :

1. Mimicking nature, water-based artificial leaf produces electricity
2. Boston Univ., Veterans Affairs find sports brain trauma may cause disease mimicking ALS
3. Wildlife Conservation Society finds wild cat mimicking monkey calls
4. Some vocal-mimicking animals, particularly parrots, can move to a musical beat
5. GigaBlitz will turn high-resolution images of nature into global inventory of organisms, habitats
6. Nanotechnologists must take lessons from nature
7. How natures best ideas inspire innovative new technologies
8. Nature helps to solve a sticky problem
9. 2011 PerkinElmer Signature Genomic Laboratories Travel Award winner announced
10. Nature paper calls for carbon labeling
11. New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: